SV2001000188A - Aminoacidos biciclicos como agentes farmaceuticos - Google Patents

Aminoacidos biciclicos como agentes farmaceuticos

Info

Publication number
SV2001000188A
SV2001000188A SV2000000188A SV2000000188A SV2001000188A SV 2001000188 A SV2001000188 A SV 2001000188A SV 2000000188 A SV2000000188 A SV 2000000188A SV 2000000188 A SV2000000188 A SV 2000000188A SV 2001000188 A SV2001000188 A SV 2001000188A
Authority
SV
El Salvador
Prior art keywords
amino acids
bicycle
pharmaceutical agents
compounds
useful
Prior art date
Application number
SV2000000188A
Other languages
English (en)
Spanish (es)
Inventor
David Clive Blakemore
Jean Marie Receveur
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of SV2001000188A publication Critical patent/SV2001000188A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14All rings being cycloaliphatic
    • C07C2602/18All rings being cycloaliphatic the ring system containing six carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14All rings being cycloaliphatic
    • C07C2602/20All rings being cycloaliphatic the ring system containing seven carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14All rings being cycloaliphatic
    • C07C2602/22All rings being cycloaliphatic the ring system containing eight carbon atoms, e.g. pentalene
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14All rings being cycloaliphatic
    • C07C2602/24All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14All rings being cycloaliphatic
    • C07C2602/26All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28Hydrogenated naphthalenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
SV2000000188A 1999-10-20 2000-10-06 Aminoacidos biciclicos como agentes farmaceuticos SV2001000188A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16072599P 1999-10-20 1999-10-20

Publications (1)

Publication Number Publication Date
SV2001000188A true SV2001000188A (es) 2001-09-07

Family

ID=22578159

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2000000188A SV2001000188A (es) 1999-10-20 2000-10-06 Aminoacidos biciclicos como agentes farmaceuticos

Country Status (50)

Country Link
US (2) US6689906B1 (2)
EP (2) EP1506955B1 (2)
JP (2) JP3632191B2 (2)
KR (2) KR100593349B1 (2)
CN (1) CN1165518C (2)
AP (2) AP2004003186A0 (2)
AR (2) AR026087A1 (2)
AT (2) ATE358116T1 (2)
AU (2) AU778871B2 (2)
BG (2) BG108860A (2)
BR (1) BR0014972B1 (2)
CA (1) CA2386297C (2)
CO (1) CO5280060A1 (2)
CR (1) CR6620A (2)
CU (1) CU23112A3 (2)
CZ (1) CZ295960B6 (2)
DE (2) DE60034157T2 (2)
DO (1) DOP2000000083A (2)
DZ (1) DZ3197A1 (2)
EA (1) EA005206B1 (2)
EC (1) ECSP045393A (2)
EE (1) EE200200211A (2)
ES (2) ES2237464T3 (2)
GE (1) GEP20043297B (2)
GT (2) GT200000183AA (2)
HK (1) HK1049826B (2)
HN (1) HN2000000224A (2)
HR (2) HRP20040709A2 (2)
HU (1) HUP0203325A3 (2)
IL (3) IL149143A0 (2)
IS (2) IS6348A (2)
MA (1) MA26842A1 (2)
MX (1) MXPA02003229A (2)
MY (1) MY127678A (2)
NO (2) NO20021780D0 (2)
NZ (1) NZ517961A (2)
OA (1) OA12070A (2)
PA (1) PA8505201A1 (2)
PE (1) PE20010740A1 (2)
PL (1) PL354607A1 (2)
PT (1) PT1226110E (2)
SI (1) SI1226110T1 (2)
SK (1) SK5232002A3 (2)
SV (1) SV2001000188A (2)
TR (2) TR200201094T2 (2)
TW (2) TWI225855B (2)
UA (1) UA72931C2 (2)
WO (1) WO2001028978A1 (2)
YU (2) YU73004A (2)
ZA (1) ZA200202543B (2)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
PL359872A1 (en) * 2000-06-26 2004-09-06 Warner-Lambert Company Gabapentin analogues for sleep disorders
US6620829B2 (en) 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
EP1226820A1 (en) 2001-01-26 2002-07-31 Warner-Lambert Company Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders
BR0208922A (pt) * 2001-04-19 2004-04-20 Warner Lambert Co Aminoácidos bicìclicos ou tricìclicos fundidos
GB2375108A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Production of a bicycloheptanone
GB2375109A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Process for preparing bicyclic amino acid
CA2449729C (en) * 2001-06-11 2009-11-03 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CN1625393A (zh) 2002-01-31 2005-06-08 沃纳-兰伯特公司 治疗耳鸣的α2δ配体
PL372210A1 (en) * 2002-02-22 2005-07-11 Warner-Lambert Company Llc Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
WO2004002462A2 (en) * 2002-06-27 2004-01-08 Warner-Lambert Company Llc Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
JP2005539092A (ja) * 2002-08-15 2005-12-22 ファイザー・インク 縮合二環式または三環式アミノ酸の治療における使用
GB0223072D0 (en) 2002-10-04 2002-11-13 Pfizer Ltd Cyclic nitromethyl acetic acid derivatives
US7018818B2 (en) 2002-10-04 2006-03-28 Pfizer Inc. Intermediates in the preparation of therapeutic fused bicyclic amino acids
US7060727B2 (en) 2002-12-11 2006-06-13 Xenoport, Inc. Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
AU2003303041B2 (en) 2002-12-13 2008-07-24 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
NZ540591A (en) 2002-12-13 2008-03-28 Warner Lambert Co Pregabalin derivatives for the treatment of fibromyalgia and other disorders
AU2004271800A1 (en) 2003-09-12 2005-03-24 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
CA2673545A1 (en) 2006-12-22 2008-07-03 Recordati Ireland Limited Combination therapy of lower urinary tract disorders with .alpha.2.delta. ligands and nsaids
EP2657219B1 (en) 2007-09-28 2014-12-10 Daiichi Sankyo Company, Limited Intermediate for producing bicyclic y-amino acid derivative
JP5557292B2 (ja) 2009-03-26 2014-07-23 第一三共株式会社 二環性γ−アミノ酸誘導体の製造方法
EP2719676B1 (en) 2011-06-08 2017-12-13 Daiichi Sankyo Company, Limited Method for producing bicyclic compound via iminium salt
WO2012169475A1 (ja) 2011-06-08 2012-12-13 第一三共株式会社 クライゼン転位反応による二環性化合物の製造方法
IN2014MN01046A (2) 2011-12-15 2015-05-01 Daiichi Sankyo Companyltd
EP2837689B1 (en) 2012-04-10 2017-02-15 Daiichi Sankyo Company, Limited Optical resolution method for bicyclic compound using enzyme
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
TWI635071B (zh) 2013-07-08 2018-09-11 第一三共股份有限公司 光學活性二環γ-胺基酸衍生物及其製造方法
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
CN113045410A (zh) * 2021-03-29 2021-06-29 华东理工大学 一种双环降二萜类化合物及其合成基因及制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641129A (en) 1969-06-17 1972-02-08 Merck & Co Inc Antifibrinolytic compounds
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
HUP0004310A3 (en) 1997-10-27 2001-11-28 Warner Lambert Co Cyclic amino acids, and derivatives thereof and pharmaceutical compositions comprising the said compounds as active agents

Also Published As

Publication number Publication date
KR100593349B1 (ko) 2006-06-26
YU73004A (sh) 2005-11-28
ECSP045393A (es) 2004-10-23
ZA200202543B (en) 2003-09-23
MY127678A (en) 2006-12-29
ES2282785T3 (es) 2007-10-16
IS6348A (is) 2002-04-17
CA2386297A1 (en) 2001-04-26
CN1382118A (zh) 2002-11-27
NO20043663L (no) 2002-04-16
JP2003512348A (ja) 2003-04-02
CZ295960B6 (cs) 2005-12-14
DE60019628D1 (de) 2005-05-25
SI1226110T1 (en) 2005-08-31
KR20060013701A (ko) 2006-02-13
JP3744928B2 (ja) 2006-02-15
TR200500221T2 (tr) 2005-03-21
IL164060A0 (en) 2005-12-18
EA200200293A1 (ru) 2002-10-31
US6689906B1 (en) 2004-02-10
OA12070A (en) 2003-11-10
BG108860A (en) 2006-03-31
HUP0203325A2 (hu) 2003-02-28
CN1165518C (zh) 2004-09-08
ATE293590T1 (de) 2005-05-15
PA8505201A1 (es) 2002-08-29
AU778871B2 (en) 2004-12-23
CA2386297C (en) 2010-02-09
HK1049826B (zh) 2005-02-25
HK1049826A1 (en) 2003-05-30
MA26842A1 (fr) 2004-12-20
AP2004003186A0 (en) 2004-12-31
JP3632191B2 (ja) 2005-03-23
EP1506955A1 (en) 2005-02-16
DE60019628T2 (de) 2006-01-19
KR20020040900A (ko) 2002-05-30
HN2000000224A (es) 2001-04-11
HRP20020428A2 (en) 2005-02-28
DE60034157T2 (de) 2007-12-13
EP1506955B1 (en) 2007-03-28
NO20021780L (no) 2002-04-16
DE60034157D1 (de) 2007-05-10
NO20021780D0 (no) 2002-04-16
CU23112A3 (es) 2006-02-27
EP1226110B1 (en) 2005-04-20
TR200201094T2 (tr) 2002-09-23
CR6620A (es) 2004-02-02
AU2005201268A1 (en) 2005-04-21
UA72931C2 (uk) 2005-05-16
BR0014972B1 (pt) 2011-09-06
SK5232002A3 (en) 2003-07-01
MXPA02003229A (es) 2002-09-30
DZ3197A1 (fr) 2001-04-26
AR026087A1 (es) 2002-12-26
EE200200211A (et) 2003-06-16
ES2237464T3 (es) 2005-08-01
IL149143A (en) 2007-02-11
HUP0203325A3 (en) 2003-12-29
BG106719A (bg) 2003-02-28
US20040152779A1 (en) 2004-08-05
PL354607A1 (en) 2004-01-26
JP2005036009A (ja) 2005-02-10
NZ517961A (en) 2002-12-20
IS7497A (is) 2004-10-08
PE20010740A1 (es) 2001-07-27
EA005206B1 (ru) 2004-12-30
IL149143A0 (en) 2002-11-10
GEP20043297B (en) 2004-01-12
GT200000183A (es) 2000-10-19
KR100566462B1 (ko) 2006-03-31
WO2001028978A1 (en) 2001-04-26
AU1092001A (en) 2001-04-30
ATE358116T1 (de) 2007-04-15
BR0014972A (pt) 2002-07-16
AP2002002517A0 (en) 2002-06-30
YU29302A (sh) 2005-06-10
AR045456A2 (es) 2005-10-26
US6835751B2 (en) 2004-12-28
TWI225855B (en) 2005-01-01
PT1226110E (pt) 2005-07-29
HRP20040709A2 (en) 2004-12-31
DOP2000000083A (es) 2002-03-30
CO5280060A1 (es) 2003-05-30
EP1226110A1 (en) 2002-07-31
TW200505824A (en) 2005-02-16
HRP20020428B1 (en) 2006-02-28
CZ20021310A3 (cs) 2003-05-14
GT200000183AA (es) 2005-06-17

Similar Documents

Publication Publication Date Title
SV2001000188A (es) Aminoacidos biciclicos como agentes farmaceuticos
PA8543501A1 (es) Aminoácidos bicíclicos o tricíclicos condensados
CR7785A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
PA8660801A1 (es) Anticuerpos antiamiloides humanizados
UY28817A1 (es) Compuestos de imidazol para el tratamiento de trastornos neurodegerativos
CL2011002206A1 (es) Compuestos derivados de benzofurano sustituidos, moduladores del señalador igf1 o activador de la proteina quinasa b; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades del snc, tales como alzheimer, entre otras.
ES2176668T3 (es) Aminoacidos ciclicos novedosos como agentes farmaceuticos.
UY28450A1 (es) Compuestos heteroarilo de 6 miembros para el tratamiento de trastornos neurodegenerativos.
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
UY28484A1 (es) Compuestos para el tratamiento de trastornos neurodegenerativos
CL2011002766A1 (es) Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras.
GT200500378A (es) Macrolidos
BR0304218A (pt) ésteres alicìclicos com fragrância de almìscar
ECSP034804A (es) Aminoácidos bicíclicos o tricíclicos condensados
CL2007003223A1 (es) Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades.
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
GT200700097A (es) Nuevos derivados de fenilpiridinilpiperazina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
CL2010001429A1 (es) Compuestos derivados de piperazinilo, moduladores del receptor p75ntr de neurotrofinas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades neurodegenerativas centrales y perifericas, depresion, afecciones cardiovasculares y cancer.
GT200400231A (es) Compuestos de sulfoniltetrahidro-3h-benzo(e)indol-8-amina como ligandos de la 5-hidroxitriptamina-6.
ECSP088280A (es) Compuestos de imidazol para el tratamiento de trastornos neurológicos
DOP2005000049A (es) Compuestos de sulfonamidas para el tratamiento de trastornos neurodegererativos
ES2187030T3 (es) Una nueva sal.
PA8608601A1 (es) Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos
PT1682162E (pt) Utilização de opuntia para a produção de um medicamento para o tratamento da depressão
UY29823A1 (es) Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones

Legal Events

Date Code Title Description
FG Grant
FD Lapse